Charles River Laboratories's revenue was $4.02bn in fiscal 2025, down 0.9% on the year before. Since fiscal 2009 ($1.17bn) it has grown at a compound 8.0% a year. Over the last twelve months it was $4.00bn.
Revenue history
US$ millions unless shown otherwise.
Fiscal years, plus the last twelve months (LTM) when newer.
Charles River Laboratories: revenue history, annual
Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.
Where the revenue comes from
Fiscal year to December 27, 2025
Discovery and Safety Assessment$2.4B
Research Models and Services$846M
Manufacturing Support$766M
Segments
Line of business
Revenue
Share
YoY
Discovery and Safety Assessment
$2.4B
59.8%
▼ 2.0%
Research Models and Services
$846M
21.1%
▲ 2.0%
Manufacturing Support
$766M
19.1%
▼ 0.4%
Services$3.3B
Products$765M
Products and services
Line of business
Revenue
Share
YoY
Services
$3.3B
80.9%
▼ 1.6%
Products
$765M
19.1%
▲ 2.6%
United States$2.1B
Europe$1.1B
Canada$501M
Asia Pacific$205M
Other$64.9M
Geography
Region
Revenue
Share
YoY
United States
$2.1B
53.3%
▼ 4.4%
Europe
$1.1B
27.5%
▲ 2.3%
Canada
$501M
12.5%
▲ 3.9%
Asia Pacific
$205M
5.1%
▲ 4.1%
Other
$64.9M
1.6%
▲ 22.8%
From Charles River Laboratories's 10-K filed February 18, 2026, as tagged in the filing.
View filing. Indented rows are part of the
line above; their share is of that line. In the bars, the
faint bar behind is the year before.
Revenue against peers
Life Sciences Tools & Services: the closest covered companies by revenue. Last twelve months.
